BioNTech Bolsters Cancer Immunotherapy Ambitions In Pact With Cash-Poor Ryvu

 
• By Joseph Haas

Deal Snapshot: German firm gets license rights to Ryvu’s STING agonist portfolio in addition to collaborating on immunomodulators. Ryvu adds need cash via upfront and equity payments from BioNTech.

Cash infusion
Ryvu gets needed infusion of cash in tie-up with BioNTech • Source: Shutterstock

More from Deals

More from Business